NeOnc to present Phase 1 dose-escalation data from NEO212 trial on March 4 call

NEONC TECHNOLOGIES HOLDINGS, INC.

Investor conference call scheduled for March 4, 2026 at 9:00 a.m. ET to present initial Phase 1 dose-escalation results from NEO212-01 trial.
Phase 1 portion evaluated oral NEO212 in CNS malignancies; data includes safety, toxicity, PK, and regulatory next steps.
Featured participants: Dr. Henry Friedman (Duke), Dr. Alexandra Miller (NYU Langone), plus NTHI management.
NEO212 is a proprietary bioconjugated temozolomide platform with FDA Fast-Track and IND status for CNS cancers.
No specific data disclosed in this release; full presentation will occur on the call.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.